Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
Quick answer
Retatrutide (Lilly) is an investigational medicine being studied for weight loss. Phase 3 TRIUMPH trials have reported results, and Lilly says it plans to file with the FDA.
FDA status: Investigational, not FDA-approved. Source: NEJM .
In a 48-week phase 2 trial, people on the highest dose lost an average of 24.2% of body weight, compared with 2.1% on placebo.
Last reviewed November 1, 2026 by the PeptideX team. Educational info, not medical advice. PeptideX doesn't give dosing advice. Talk to a licensed clinician.
FDA status
Investigational
Investigational. The FDA has not approved retatrutide for any use. Lilly says it cannot be legally sold or marketed for human use.
Lilly, July 23, 2026By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 180 PubMed citations indexed.
Products sold as "research use only" are not approved for human use. FDA warning.
Triple agonist targeting GLP-1, GIP, and glucagon receptors for additive metabolic benefits; early trials show superior weight reduction vs dual agonists.
What the literature studies
Triple GLP-1/GIP/Glucagon Agonist
Evidence tier
Human RCT
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
Phase III trials ongoing as of 2025
Retatrutide trial status tracker: StartReta
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.
Retatrutide is Lilly's investigational triple agonist (GIP/GLP-1/glucagon); phase 3 showed up to 28.3% weight loss vs 2.2% on placebo, Lilly plans to file with FDA in Q1 2027, and it is not approved anywhere.
A once-weekly injectable peptide that activates GIP, GLP-1 and glucagon receptors [R1].
Investigational; not approved by any regulator. Lilly says it cannot be legally sold or marketed for human use, so online "research" retatrutide is not Lilly product [R3]. Lilly plans a US submission in Q1 2027 [R3][R5]. RE-CHECK after Lilly's Oct 29 2026 Q3 results.
Preclinical work established the triple-agonist design [R1]; the human data now outweigh it.
Last checked 2026-10-27
Education only. Not medical advice. No dosing guidance. peptidex.ai does not sell peptides or link to sellers.